Specialists in hearing, HIV come together to study AIDS patients

November 03, 2009

Specialists in HIV and in hearing at the University of Rochester Medical Center are teaming up to measure the hearing of people with AIDS.

The five-year study is believed to be the first large study of its kind testing the hearing of people with HIV/AIDS and comparing the results with those from people without HIV. The new effort, supported by a $1.9 million grant from the National Institute on Deafness and Other Communication Disorders, is the result of collaboration between hearing experts and experts on HIV and AIDS.

The study is led by Amneris Luque, M.D., associate professor of Medicine and director of Strong Memorial Hospital's AIDS Clinic, which provides care for more than 900 patients. The project brings together experts in the nervous system and the immune system, both of which are involved in many types of hearing loss. The first of 360 participants who will take part in the study enrolled last week.

Luque will work closely with hearing researcher Robert Frisina, Ph.D., professor of Otolaryngology, Biomedical Engineering, and Neurobiology and Anatomy. Frisina's team, which is based at the Medical Center as well as the National Technical Institute for the Deaf, is widely regarded as one of the premier groups in the world looking at age-related hearing loss.

Luque says that since AIDS was recognized nearly three decades ago, hearing loss among some patients has been reported. However, these reports have been scattered and unconfirmed.

"There has not been a systematic study looking at hearing function in people with HIV," said Luque. "If there is hearing impairment, it could be related to the disease itself; it might be related to infections that our patients with AIDS are prone to getting; or it might be related to the medications used to treat the disease."

Luque notes that some scientists have found evidence that people with HIV/AIDS may be aging prematurely compared to people without HIV. The team will look closely at whether a similar acceleration of aging may play a role in the hearing of people with HIV.

In addition, of course, many people without HIV also experience hearing loss. Causes of hearing loss can include noise exposure, medications used to treat conditions like cancer or other infections, or heredity. Sorting out those causes from other processes unique to people with HIV is challenging.

"We're trying to tease out what is happening in people with HIV," said Luque. "Is there something inherent about the infection that may be involved in hearing loss?"

Participants in the study will undergo periodic, rigorous testing of their hearing. Scientists will study patients at various stages of HIV infection, including some infected people known as "long-term non-progressors" or "elite controllers," people in whom the infection hasn't advanced even without medication.

The team will compare the results in HIV/AIDS patients to results in healthy people who have had similar hearing tests conducted at the International Center for Hearing and Speech Research, where Frisina is associate director. That database includes extensive information about the hearing of more than 1,400 healthy people who have had similar testing done.

University of Rochester Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.